Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Primary Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS, KOV-04)

NCT05827523 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT05827523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05827523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Primary Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS, KOV-04)
Lead sponsor
National Cancer Center, Korea
Phase
Phase 3
Overall status
Recruiting
Start date
May 31, 2023
Completion date
December 31, 2030
Enrollment
520 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer